ClinicalTrials.gg
CompletedNCT01664039Updated Aug 3, 2015Results posted

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

A Phase 4 interventional study of Travoprost 0.004% ophthalmic solution and Bimatoprost 0.01% ophthalmic solution in Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-03.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.

Enrollment
17th of 39
104 · median 89
Started
2012
with 1 other
Phase 4
25 of 42
none open now
Registered
34th of 42
by date
Lead sponsor
27 of 42
Alcon Research

Among the 42 studies testing travoprost in Glaucoma, this one is the 17th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2012, is one of 25 in phase 4, and was the 34th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing travoprost in Glaucoma as a file.
02

Study summary

The purpose of this study is evaluate effects of TRAVATAN® versus LUMIGAN® on intraocular pressure (IOP) and ocular surface and inflammatory biomarkers.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension

Keywords

  • Glaucoma
  • Ocular hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with either open-angle glaucoma or ocular hypertension in at least one eye and be treatment naïve to any glaucoma treatment.
  • Intraocular pressure (IOP) between 19 mmHg and 35 mmHg in at least one eye, which would be the study eye.
  • IOP considered to be safe (in the opinion of the investigator), in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the study period.
  • Able to follow instructions and be willing and able to attend all study visits.
  • Best corrected Snellen visual acuity of 6/60 (20/200, 1.0 LogMAR) or better in each eye.
  • Must read, sign, and date an Ethics Committee-approved form.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Known medical history of allergy, or poor tolerance to any components of the study medications to be used in this study that is deemed in the opinion of the Principal Investigator.
  • Any abnormality preventing reliable applanation tonometry in either eye.
  • Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye.
  • Prior treatment of dry eye with punctal plugs, punctal cautery, Restasis® or topical ocular .
  • History of ocular surface disease (dry eye) or current/prior use of dry eye medications (either over-the counter or prescription medications).
  • Contact lens wear.
  • Intraocular conventional surgery or laser surgery in either eye that is less than three months prior to the Screening Visit.
  • Use of any systemic medications known to affect IOP (e.g., oral beta-adrenergic blockers, alpha-agonists and blockers, angiotensin converting enzyme inhibitors and calcium channel blockers), which have not been on a stable course for at least 7 days prior to Screening Visit or an anticipated change in the dosage during the course of the study.
  • Women of not using reliable means of , are pregnant, or lactating.
  • Unwilling to risk the possibility of darkened iris or eyelash changes.
  • Participation in any other study within 30 days prior to the Screening Visit.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    TRAVATAN

    Travoprost 0.004% ophthalmic solution with Polyquad®, 1 drop to the study eye(s), once a day in the evening, for 6 months

    Drug: Travoprost 0.004% ophthalmic solution

  • Active comparator
    LUMIGAN

    Bimatoprost 0.01% ophthalmic solution with BAK, 1 drop to the study eye(s), once a day in the evening, for 6 months

    Drug: Bimatoprost 0.01% ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Intraocular Pressure (IOP) at Month 6

    IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

    Time frame: Baseline (Day 0), Month 6

Secondary outcomes

  1. Mean Change From Baseline in IOP at Week 6 and Month 3

    IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg. A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

    Time frame: Baseline (Day 0), Week 6, Month 3

  2. Percentage of Subjects Who Reached Target IOP at Each Visit

    IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg. Target IOP was defined as ≤ 18 mmHg. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

    Time frame: Week 6, Month 3, Month 6

  3. Number of Subjects With Change From Baseline in Ocular Hyperaemia by Grade at Each Visit

    Ocular Hyperaemia (excess of blood in the white of the eyes (sclera)) was graded by the investigator on a 4-point scale where 0=None/Trace, 1=Mild, 2=Moderate, and 3=Severe. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

    Time frame: Baseline (Day 0), Week 6, Month 3, Month 6

  4. Number of Subjects With Change From Baseline in Corneal Staining by Grade at Month 3 and Month 6

    Corneal staining was assessed after ophthalmic dye was instilled in the eye. The upper eyelid was lifted slightly, and the eye was compared to grading panels. Corneal staining was graded on a scale from 0 (absent) to 5 (severe). One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

    Time frame: Baseline (Day 0), Month 3, Month 6

  5. Number of Subjects With Change From Baseline in Conjunctiva Staining by Grade at Month 3 and Month 6

    Conjunctiva staining was assessed after ophthalmic dye was instilled in the eye. The upper eyelid was lifted slightly, and the eye was compared to grading panels. Conjunctiva staining was graded on a scale from 0 (absent) to 5 (severe). One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

    Time frame: Baseline (Day 0), Month 3, Month 6

  6. Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Month 3 and Month 6

    The OSDI questionnaire (used to measure vision-related function, ocular symptoms, visual function, and environmental factors that may affect vision) was answered by the subject. Each of the 12 items was scored on a 0-4 Likert scale, where 0 is "None of the time" and 4 is "All of the time." A resultant overall 0-100 score was calculated, with higher scores representing greater disability. A negative number change represents a perceived improvement in ocular health.

    Time frame: Baseline (Day 0), Month 3, Month 6

  7. Mean Change From Baseline In Tear Film Break Up Time (TBUT) at Month 3 and Month 6

    TBUT (the time required for dry spots to appear on the corneal surface after blinking) was assessed by the investigator using slit lamp examination . A longer break up time is a sign of a more stable tear film. A positive number change from baseline indicates improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

    Time frame: Baseline (Day 0), Month 3, Month 6

07

Results

Posted Jul 14, 2015

Participant flow

Subjects were recruited from 2 study centers located in Slovenia.

Participant flow — Overall Study
MilestoneTRAVATANLUMIGAN
Started5252
Completed4643
Not completed69
Withdrew: Adverse event34
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject13
Withdrew: Noncompliance11

Outcome measures

PrimaryMean Change From Baseline in Intraocular Pressure (IOP) at Month 6

IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

Time frame:
Baseline (Day 0), Month 6
Reported as:
Mean · mmHg
Mean Change From Baseline in Intraocular Pressure (IOP) at Month 6
mmHgTRAVATANLUMIGAN
Baseline (Day 0)24.66 ± 3.6524.59 ± 4.14
Change from Baseline at Month 6, n=46,43-7.61 ± 4.32-7.35 ± 3.84
SecondaryMean Change From Baseline in IOP at Week 6 and Month 3

IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg. A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

Time frame:
Baseline (Day 0), Week 6, Month 3
Reported as:
Mean · mmHg
Mean Change From Baseline in IOP at Week 6 and Month 3
mmHgTRAVATANLUMIGAN
Change from Baseline at Week 6, n=46,46-7.50 ± 3.80-7.02 ± 3.28
Change from Baseline at Month 3, n=46,44-7.96 ± 3.71-7.82 ± 3.15
SecondaryPercentage of Subjects Who Reached Target IOP at Each Visit

IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg. Target IOP was defined as ≤ 18 mmHg. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

Time frame:
Week 6, Month 3, Month 6
Reported as:
Number · percentage of participants
Percentage of Subjects Who Reached Target IOP at Each Visit
percentage of participantsTRAVATANLUMIGAN
Week 6, n=46,4669.656.5
Month 3, n=46,4471.770.5
Month 6, n=46,4373.967.4
SecondaryNumber of Subjects With Change From Baseline in Ocular Hyperaemia by Grade at Each Visit

Ocular Hyperaemia (excess of blood in the white of the eyes (sclera)) was graded by the investigator on a 4-point scale where 0=None/Trace, 1=Mild, 2=Moderate, and 3=Severe. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

Time frame:
Baseline (Day 0), Week 6, Month 3, Month 6
Reported as:
Number · participants
Number of Subjects With Change From Baseline in Ocular Hyperaemia by Grade at Each Visit
participantsTRAVATANLUMIGAN
Baseline, Grade 04031
Baseline, Grade 1917
Baseline, Grade 211
-1 Grade Change from Baseline at Week 621
0 Grade Change from Baseline at Week 62023
+1 Grade Change from Baseline at Week 62320
+2 Grade Change from Baseline at Week 612
-1 Grade Change from Baseline at Month 321
0 Grade Change from Baseline at Month 31315
+1 Grade Change from Baseline at Month 32526
+2 Grade Change from Baseline at Month 362
-1 Grade Change from Baseline at Month 601
0 Grade Change from Baseline at Month 62015
+1 Grade Change from Baseline at Month 62325
+2 Grade Change from Baseline at Month 632
SecondaryNumber of Subjects With Change From Baseline in Corneal Staining by Grade at Month 3 and Month 6

Corneal staining was assessed after ophthalmic dye was instilled in the eye. The upper eyelid was lifted slightly, and the eye was compared to grading panels. Corneal staining was graded on a scale from 0 (absent) to 5 (severe). One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

Time frame:
Baseline (Day 0), Month 3, Month 6
Reported as:
Number · participants
Number of Subjects With Change From Baseline in Corneal Staining by Grade at Month 3 and Month 6
participantsTRAVATANLUMIGAN
Baseline, Grade 04139
Baseline, Grade 189
Baseline, Grade 211
-1 Grade Change from Baseline at Month 374
0 Grade Change from Baseline at Month 33333
+1 Grade Change from Baseline at Month 367
-1 Grade Change from Baseline at Month 647
0 Grade Change from Baseline at Month 62825
+1 Grade Change from Baseline at Month 61310
+2 Grade Change from Baseline at Month 611
SecondaryNumber of Subjects With Change From Baseline in Conjunctiva Staining by Grade at Month 3 and Month 6

Conjunctiva staining was assessed after ophthalmic dye was instilled in the eye. The upper eyelid was lifted slightly, and the eye was compared to grading panels. Conjunctiva staining was graded on a scale from 0 (absent) to 5 (severe). One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

Time frame:
Baseline (Day 0), Month 3, Month 6
Reported as:
Number · participants
Number of Subjects With Change From Baseline in Conjunctiva Staining by Grade at Month 3 and Month 6
participantsTRAVATANLUMIGAN
Baseline, Grade 04439
Baseline, Grade 169
Baseline, Grade 201
Month 3, -1 Grade Change from Baseline66
Month 3, 0 Grade Change from Baseline3633
Month 3, +1 Grade Change from Baseline35
Month 3, +2 Grade Change from Baseline10
Month 6, -1 Grade Change from Baseline47
Month 6, 0 Grade Change from Baseline3126
Month 6, +1 Grade Change from Baseline119
Month 6, +2 Grade Change from Baseline01
SecondaryMean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Month 3 and Month 6

The OSDI questionnaire (used to measure vision-related function, ocular symptoms, visual function, and environmental factors that may affect vision) was answered by the subject. Each of the 12 items was scored on a 0-4 Likert scale, where 0 is "None of the time" and 4 is "All of the time." A resultant overall 0-100 score was calculated, with higher scores representing greater disability. A negative number change represents a perceived improvement in ocular health.

Time frame:
Baseline (Day 0), Month 3, Month 6
Reported as:
Mean · units on a scale
Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Month 3 and Month 6
units on a scaleTRAVATANLUMIGAN
Baseline (Day 0)14.6 ± 14.810.6 ± 10.5
Change from Baseline at Month 3, n=44,43-0.3 ± 12.20.0 ± 10.4
Change from Baseline at Month 6, n=44,420.4 ± 16.21.7 ± 14.3
SecondaryMean Change From Baseline In Tear Film Break Up Time (TBUT) at Month 3 and Month 6

TBUT (the time required for dry spots to appear on the corneal surface after blinking) was assessed by the investigator using slit lamp examination . A longer break up time is a sign of a more stable tear film. A positive number change from baseline indicates improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis.

Time frame:
Baseline (Day 0), Month 3, Month 6
Reported as:
Mean · seconds
Mean Change From Baseline In Tear Film Break Up Time (TBUT) at Month 3 and Month 6
secondsTRAVATANLUMIGAN
Baseline (Day 0)10.7 ± 2.711.7 ± 3.2
Change from Baseline at Month 3, n=46,44-1.6 ± 5.3-1.8 ± 4.0
Change from Baseline at Month 6, n=46,43-2.2 ± 3.6-2.2 ± 5.1

Adverse events

Collected over Adverse events (AEs) were collected for the duration of the study (Sep 2012 - Jun 2014). This analysis population includes all subjects who received at least 1 dose of either study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TRAVATAN—0/51 (0%)0/51 (0%)
LUMIGAN—1/49 (2%)0/49 (0%)
Most frequent serious events
Most frequent serious events
EventTRAVATANLUMIGAN
ThromboendarterectomySurgical and medical procedures0/511/49

Baseline characteristics

This analysis population includes all randomized subjects.

Age, Customized
Age, Customized(participants)TRAVATANLUMIGANTotal
Under 60 years252651
60 or more years272653
Sex: Female, Male
Sex: Female, Male(Participants)TRAVATANLUMIGANTotal
Female351651
Male173653
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2012
First posted
Aug 14, 2012
Start
Sep 2012
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Jul 14, 2015
Last update
Aug 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01664039
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Aug 14, 2012
Start date
Sep 2012
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Jul 14, 2015
Last update
Aug 3, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion